Milan, Italy

Stefano Poli


Average Co-Inventor Count = 2.3

ph-index = 6

Forward Citations = 250(Granted Patents)


Location History:

  • Quinto De Stampi-Rozzano, IT (1989 - 1994)
  • Milan, IT (1987 - 1998)
  • Quinto De'Stampi, IT (1997 - 2000)

Company Filing History:


Years Active: 1987-2000

Loading Chart...
12 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Stefano Poli

Introduction

Stefano Poli is a prominent inventor based in Milan, Italy, known for his significant contributions to the field of pharmaceuticals. With a total of 12 patents to his name, he has made remarkable advancements in the development of pharmaceutical compositions.

Latest Patents

Among his latest patents are the "Diastereomerically pure 3-oxo and 3-thioxo-4-aza-androstan derivatives" and "Muscle relaxant pharmaceutical compositions." The latter invention relates to pharmaceutical compositions for parenteral administration. These compositions comprise an effective amount of a neuromuscular blocking agent to produce muscular relaxation, along with at least one zwitterionic substance that has an isoionic point not greater than 7. The zwitterionic substance is present in an amount ranging from about 2 to about 30 percent by weight, based on the weight of the composition. The resulting composition maintains a pH of less than 7.

Career Highlights

Stefano Poli has had a successful career, working with notable companies such as Poli Industria Chimica Spa and Polichem S.a. His work has significantly impacted the pharmaceutical industry, particularly in the area of muscle relaxants.

Collaborations

Throughout his career, Stefano has collaborated with esteemed colleagues, including Germano Coppi and Lucio Del Corona. These partnerships have further enhanced his innovative capabilities and contributions to the field.

Conclusion

Stefano Poli's work exemplifies the spirit of innovation in pharmaceuticals, with his patents paving the way for advancements in muscle relaxant compositions. His contributions continue to influence the industry and improve therapeutic options for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…